rafutrombopag
Radiotherapy Side Effect
Sir Run Run Shaw HospitalSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 89/ 100
Competitive context
7 Active assets in the Radiotherapy Side Effect cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FILGRASTIM IRCCS San Raffaele | Phase 3 | BB |
Amifostine Alliance for Clinical Trials in Oncology | Phase 3 | BB |
CIS-DIAMMINEDICHLOROPLATINUM II Sun Yat-sen University | Phase 3 | BB |
ETOPOSIDE Sun Yat-sen University | Phase 3 | BB |
Carboplatin Sun Yat-sen University | Phase 3 | BB |
View all 37 →
Same molecule, other indications
rafutrombopag is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →